Archive for the ‘USPTO Practice and Policy’ Category

Defining the Abstract and Conceptual – USPTO Issues “Guidance” Post-Bilski

Monday, August 2nd, 2010

Before I write another word, I want to recognize and applaud the intellectual and logistical effort it must have taken for Director Kappos and his helpers to put together six pages of “Interim Guidance For Determining Subject Matter Eligibility for Process Claims in View of Bilski v. Kappos,” 75 Fed. Reg. 43922 (July 27, 2010), (attached at end of post) “for its personnel to use when determining subject matter eligibility under U.S.C 101…The Office is especially interested in receiving comments regarding the scope and extent of the holding in Bilski.” The Office deserves our attention.

In my last post, I considered the difficulty in setting standards by which to determine whether or not a claim to a process is an abstract idea or rather does it involve concrete technology. The Interim Guidance (an official “Notice”) tackles this question head on. The Notice cites Chakrabarty as endorsing an expansive view of what constitutes a “new and useful process,” limited by the exceptions “laws of nature, physical phenomena and abstract ideas.” The Notice observes that “the Office had used the ‘abstract idea’ exception in cases where a claimed ‘method’ did not sufficiently recite a physical instantiation…Thus, the Bilski claims were said to be drawn to an ‘abstract idea’ despite the fact that they included steps of initiating transactions. The ‘abstractness’ is in the sense that there are no limitations as to the mechanism for entering into the transactions.” Notice at 93924. (Such limitations create the instantiation, a word I had to look up.)

The Notice discusses, and goes on to outline, four primary factors weighing toward patent eligibility and four primary factors weighing against it. The first step in the “pro” column is the express or inherent recitation of a machine or transformation. Likewise, the first and second “con” steps are no, or insufficient recitation, of a machine or transformation (again, express or inherent). Then it gets interesting. Factor three of the “pro” list is that the claim is directed toward a practical application of a law of nature, that limits the execution of the steps. The “con” factor is that the claim is not directed to the application of a law of nature and would monopolize a natural force or patent a scientific fact. A “con” example might be a claim, not to a diagnostic assay for a vitamin deficiency or cancer, but to the underlying fact that human blood contains certain amounts of homocysteine or PSA.

The fourth “pro” factor begins to cross into even less intellectually stable realms: “The claim is more than a mere statement of a concept.” The “con” factor mirrors it, “The claim is a mere statement of a general concept…use of the concept, as expressed in the method would effectively grant a monopoly over the concept.” But on reflection, these are more practical factors then they might first appear. Every prep/pros practitioner has encountered inventors who want to patent concepts or bright ideas, as opposed to inventions. Such a general concept might be stated as correlating mutations in genes to a propensity to develop cancer. How about “A car that runs on water as fuel.” I once had a professor approach me to patent his idea to develop a pig with organs that would not give rise to a rejection response when transplanted into humans. This was indeed a bright idea, but he had no idea how to create such a pig. This sort of “invention” was so common in the early days of biotechnology, that I wrote in the margins of my copy of Chemical Patent Practice (J. L. White): “You don’t patent ‘concepts’, you patent inventions; e.g., ‘power transfer’ vs. the gears that do it.” BNA PCTJ vol. 34, 264 (1987); Perkin-Elmer Corp. v Westinghouse Electric Corp.” I will leave it to you to check the cites.


bilski_guidance_27jul2010

Patent Office Says, “Have It Your Way!” For A Price.

Tuesday, June 15th, 2010

The PTO has proposed a “Three-Track Examination” option for applicants which gives them the opportunity to jump to the head of the examination line (goal: 12 mo. pendency  with first office action within two months) or to put the application on hold for up to 30 months (note to file: how can an applicant tell he/she is on this path?). The third choice is to do nothing. The program applies to applications that have not been refiled. Applications claiming foreign priority would have to apply with a search report, first official action, and a response in hand. But there are no such requirements for U.S. applicants, except possibly a limitation on the number and type of claims (to be decided). This is a lot less onerous than the requirements for accelerated examination, which require a search report, a summary of the art, etc., and the fast-tracking of applications on “Green Technology.” Both have been little used to date.

I am typing this during a break from doing interviews at the PTO (four today) and, concerns about discrimination against “foreign” applicants aside, I am for it. One of the applications I am interviewing was filed in the U.S. via a PCT in 2001. (I recently inherited this application.) The average time between (non-final) office actions has been about seven months, with a series of Examiners. Right now, it is entitled to over 1000 days of PTA. Believe me, I have a search report from the priority country. Would the client, a small pharma company, pay to speed this up with a goal of resolution in any preselected time? You betcha!

The Return Of The Magnificent Prosecution Specialists Or Just More “QA”?

Thursday, April 15th, 2010

The USPTO recently announced the creation of an ombudsman program to resolve applicant/examiner logjams in all of the Tech Centers. This is a move that the Office (and practitioners) have needed badly for a number of years, ever since the demise of the “Strong” Patent Prosecution Specialists in the pharma/biotech groups (1600/1800). Patent Prosecution Specialists like Richard Schwartz, Brian Stanton (now at NIH), and Margaret Parr were given real power to move stalled applications forward by mediating amendments acceptable to both sides or, in some cases, by simply telling the Examiner that he/she was wrong and to allow the claims in question. However, if this is simply a return to the “Weak” QA Specialist program that was no more than window dressing on the no-Patent Office, why bother? We need change we can believe in, not a PTO where Examiners are encouraged to just say “No”!

PTO Biotech/Chem/Pharma Customer Partnership Meeting Announced

Thursday, February 18th, 2010

The USPTO has announced that it will hold a meeting of the Biotechnology/Chemical/Pharmaceutical Customer Partnership on Tuesday, March 2nd, in the Madison Auditorium of the USPTO in Alexandria, VA (agenda attached). You can attend in person or via a link to join online. In the past, I have been less than enthusiastic about these events. From their start in the 90’s, they devolved from small meetings of representatives of IP law user groups with senior Examiners (I met John Doll at one of these meetings) to try to resolve differences in examination policy (e.g., what does per cent sequence identity mean?) to one-day conferences which were mostly consumed by the PTO telling us how great they were (or planned to be in the near future). But this agenda looks like it has some meat on the bones. Topics include reissue, PTA, accelerated examination and synthetic biology. Time to give it another try.

BCP 030210 _Agenda Updated

Accessing the event:

1.    Double click on the link below (or copy it into your internet browser)https://uspto.connectsolutions.com/r45099374/

2.    Select the “Enter as a Guest” option.

3.    External guests – please login using your email address

       USPTO Employees – please login using your last name, first name

4.    Click on the “Enter Room” button

5.    You will be admitted to the meeting

Assistance

If you need assistance with login, please contact Darcy Bates at (571) 272-2499 or Carrie Scott at  (571) 272-2992.